Nilotinib (5–10 μM) increased the intracellular retention of Rho-123 by 2.4±0.30- and 1.6±0.08-fold in synovial sarcoma and leiomyosarcoma cells, respectively (Fig. 6), presenting higher efficacy than the P-gp inhibitor verapamil (10 μM) used as positive control. Here, PGP is linked to synovial sarcoma.